{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:51:56Z","timestamp":1793886716209,"version":"4.8.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.fertnstert.2022.04.027","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T07:50:02Z","timestamp":1655106602000},"page":"371-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":164,"title":["Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study"],"prefix":"10.1016","volume":"118","author":[{"given":"Karen E.","family":"Elkind-Hirsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Chappell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Shaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Storment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drake","family":"Bellanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2022.04.027_bib1","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/humrep\/dep399","article-title":"The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria","volume":"25","author":"March","year":"2010","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1210\/jc.2007-1834","article-title":"Impact of obesity on the risk for polycystic ovary syndrome","volume":"93","author":"Yildiz","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib3","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/humupd\/dms030","article-title":"Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"18","author":"Lim","year":"2012","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib4","first-page":"774","article-title":"Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis","volume":"18","author":"Dunaif","year":"1997","journal-title":"Endocr Rev"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib5","first-page":"CD007506","article-title":"Lifestyle changes in women with polycystic ovary syndrome","volume":"7","author":"Moran","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib6","doi-asserted-by":"crossref","first-page":"323rv2","DOI":"10.1126\/scitranslmed.aad1811","article-title":"New therapeutic approaches for the treatment of obesity","volume":"8","author":"Saltiel","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/nu13020351","article-title":"Incretin hormones in obesity and related cardiometabolic disorders: the clinical perspective","volume":"13","author":"Micha\u0142owska","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1463-1326.2009.01075.x","article-title":"The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1\u20135 studies","volume":"11","author":"Blonde","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib9","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib10","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsboll","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/07435800.2014.966385","article-title":"Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome","volume":"40","author":"Jensterle","year":"2015","journal-title":"Endocr Res"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12902-017-0155-9","article-title":"Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial","volume":"17","author":"Jensterle","year":"2017","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib14","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1210\/jc.2008-0115","article-title":"Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome","volume":"93","author":"Elkind-Hirsch","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib15","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/cen.13454","article-title":"Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight\/obese polycystic ovary syndrome","volume":"87","author":"Liu","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.rbmo.2017.03.023","article-title":"Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial","volume":"35","author":"Nylander","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib17","unstructured":"Johnson T, Kaplan L, Ouyang P, Rizza R. National Institutes of Health. NIH Evidence based methodology workshop on Polycystic Ovary Syndrome executive summary. Bethesda, MD, USA: NIH, 2012. Available at: https:\/\/prevention.nih.gov\/sites\/default\/files\/2018-06\/FinalReport.pdf. Accessed April 29, 2013."},{"key":"10.1016\/j.fertnstert.2022.04.027_bib18","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1210\/jcem.84.10.6079","article-title":"A critical evaluation of simple methods for the estimation of free testosterone in serum","volume":"84","author":"Vermeulen","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib19","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.2337\/dc21-S002","article-title":"Classification and diagnosis of diabetes: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib20","first-page":"4755","article-title":"The effect of abdominal obesity in patients with polycystic ovary syndrome on metabolic parameters","volume":"21","author":"Franik","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/j.1550-8528.1999.tb00404.x","article-title":"The use of anthropometric and dual-energy x-ray absorptiometry (DXA) measures to estimate total abdominal and abdominal visceral fat in men and women","volume":"7","author":"Clasey","year":"1999","journal-title":"Obes Res"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib22","doi-asserted-by":"crossref","first-page":"846578","DOI":"10.1155\/2014\/846578","article-title":"Importance of android\/gynoid fat ratio in predicting metabolic and cardiovascular disease risk in normal weight as well as overweight and obese children","volume":"2014","author":"Samsell","year":"2014","journal-title":"J Obes"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib23","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib24","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib25","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1464-5491.1995.tb00399.x","article-title":"The 30 minute insulin incremental response in an oral glucose tolerance test as a measure of insulin secretion [letter; comment]","volume":"12","author":"Wareham","year":"1995","journal-title":"Diabet Med"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/eje.0.1500097","article-title":"Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies","volume":"150","author":"Ahren","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib27","doi-asserted-by":"crossref","first-page":"802","DOI":"10.7326\/0003-4819-139-10-200311180-00007","article-title":"Use of metabolic markers to identify overweight individuals who are insulin resistant","volume":"139","author":"McLaughlin","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.metabol.2011.09.009","article-title":"The association between triglyceride to high-density-lipoprotein cholesterol ratio and insulin resistance in a multiethnic primary prevention cohort","volume":"61","author":"Gasevic","year":"2012","journal-title":"Metabolism"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib29","unstructured":"Saxenda prescribing information. Available at: www.accessdata.fda. gov\/ drugsatfda_docs\/label\/2014\/206321Orig1s000lbl.pdf. Accessed September 22,\u00a02017."},{"key":"10.1016\/j.fertnstert.2022.04.027_bib30","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/17512433.2017.1292125","article-title":"GLP-1 receptor agonists in the treatment of polycystic ovary syndrome","volume":"10","author":"Lamos","year":"2017","journal-title":"Expert Rev of Clin Pharmacol"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib31","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40261-020-00942-2","article-title":"Liraglutide: new perspectives for the treatment of polycystic ovary syndrome","volume":"40","author":"Papaetis","year":"2020","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib32","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib33","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/ijo.2013.149","article-title":"Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults","volume":"38","author":"Lean","year":"2014","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1152\/physrev.1994.74.4.761","article-title":"Regional adiposity and morbidity","volume":"74","author":"Kissebah","year":"1994","journal-title":"Physiol Rev"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib35","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jclinepi.2007.08.012","article-title":"Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis","volume":"61","author":"Lee","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib36","doi-asserted-by":"crossref","first-page":"16S","DOI":"10.1038\/oby.2006.277","article-title":"Why visceral fat is bad: mechanisms of the metabolic syndrome","volume":"14","author":"Bergman","year":"2006","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/gerona\/58.2.M181","article-title":"Lifestyle intervention of hypocaloric dieting and walking reduces abdominal obesity and improves coronary heart disease risk factors in obese, postmenopausal, African-American and Caucasian women","volume":"58","author":"Nicklas","year":"2003","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib38","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/oby.21033","article-title":"The role of androgens in metabolism, obesity, and diabetes in males and females","volume":"23","author":"Navarro","year":"2015","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib39","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/humrep\/deg367","article-title":"Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet","volume":"18","author":"Crosignani","year":"2003","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib40","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1210\/jc.2008-0751","article-title":"The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome","volume":"93","author":"Thomson","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib41","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/humrep\/dew243","article-title":"Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinemic clamp studies","volume":"31","author":"Cassar","year":"2016","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib42","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20165826","article-title":"Glucagon-like peptide 1 improves insulin resistance in\u00a0vitro through anti-inflammation of macrophages","volume":"49","author":"Guo","year":"2016","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1463-1326.2009.01073.x","article-title":"The effects of glucagon-like peptide-1 on the beta cell","volume":"11","author":"Vilsb\u00f8ll","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib44","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0002-9343(01)00948-2","article-title":"Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome","volume":"111","author":"Legro","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib45","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1210\/jcem-61-5-946","article-title":"Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome","volume":"61","author":"Wild","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib47","article-title":"Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analog, significantly reduces lipids and other markers of cardiovascular risk in T2D","volume":"52","author":"Plutzky","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib48","doi-asserted-by":"crossref","first-page":"107548","DOI":"10.1016\/j.jdiacomp.2020.107548","volume":"34","author":"Elkind-Hirsch","year":"2020","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.fertnstert.2022.04.027_bib49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.endonu.2014.06.009","article-title":"Triglycerides and glucose index: a useful indicator of insulin resistance","volume":"61","author":"Unger","year":"2014","journal-title":"Endocrinol Nutr"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028222002710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028222002710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:17:37Z","timestamp":1762150657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0015028222002710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0015028222002710"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2022.04.027","relation":{},"ISSN":["0015-0282"],"issn-type":[{"value":"0015-0282","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2022.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92022 The Authors. Published by Elsevier Inc. on behalf of the American Society for Reproductive Medicine.","name":"copyright","label":"Copyright"}]}}